8 research outputs found
Salmonellosis in Lagos, Nigeria: Incidence of Plasmodium falciparum-associated Co-infection, Patterns of Antimicrobial Resistance, and Emergence of Reduced Susceptibility to Fluoroquinolones
The present study was undertaken to examine the status of antimicrobial resistance in Salmonella-associated diseases, by verifying possible emergence of reduced susceptibility to fluoroquinolones in Salmonella isolates and determining the incidence of Plasmodium falciparum-associated co-infection with Salmonella serotypes. Antimicrobial resistance in clinical isolates of Salmonellae was examined for a 12-month period. Four hundred and forty-one patients comprising two groups were recruited. Group A comprised 235 patients diagnosed by clinicians of having pyrexia, and group B included stool samples of 206 patients presenting with gastroenteritis. Samples were cultured and isolates identified, and drug susceptibility testing was performed using the standard methods. Of the 235 samples screened in group A, 42 Salmonella isolates and 107 Plasmodium spp. were identified. Of the 42 Salmonella isolates, 19 (45.2%) were Salmonella Typhi, 9 (21.4%) S. Enteritidis, and 7 (16.7%) each of S. Paratyphi and S. Arizonae. Plasmodium spp.-associated co-infection with Salmonellae was observed in 16 patients mostly in complicated typhoidal cases and S. Enteritidis-associated bacteraemia. Fiftty-three of the 206 stool samples from group B patients were confirmed positive for bacterial pathogens, made up of 35 Salmonella and 18 Shigella isolates. Of the Salmonella isolates, 18 (51.4%) were S. Enteritidis, 11 (31.4%) S. Arizonae, 4 (11.4%) S. Paratyphi, and 2 (5.7%) S. Typhi. There was no statistically significant difference (p<0.01) in antimicrobial resistance patterns exhibited among typhoidal Salmonellae isolated in 2000 and 2005. A similar trend in resistance was recorded for non-typhoidal Salmonellae (p<0.05). For the first time in Lagos, Nigeria, Salmonella isolates (10–18%) with reduced susceptibility to both ciprofloxacin and ofloxacin at MIC50 and MIC90 values of 0.015 and 0.03 μg/mL respectively were found. Despite this development, ciprofloxacin and ofloxacin remain the drug of choice for severe cases of salmonellosis, although caution should be exercised by clinicians in their pres-criptions such that fluoroquinolone antibiotic therapy is used only in laboratory-proven cases of typhoid fever and Salmonella-associated bacteraemia to preserve its efficacy
Salmonellosis in Lagos, Nigeria: Incidence of Plasmodium falciparum -associated Co-infection, Patterns of Antimicrobial Resistance, and Emergence of Reduced Susceptibility to Fluoroquinolones
The present study was undertaken to examine the status of antimicrobial
resistance in Salmonella-associated diseases, by verifying possible
emergence of reduced susceptibility to fluoroquinolones in Salmonella
isolates and determining the incidence of Plasmodium falciparum
-associated co-infection with Salmonella serotypes. Antimicrobial
resistance in clinical isolates of Salmonellae was examined for a
12-month period. Four hundred and forty-one patients comprising two
groups were recruited. Group A comprised 235 patients diagnosed by
clinicians of having pyrexia, and group B included stool samples of 206
patients presenting with gastroenteritis. Samples were cultured and
isolates identified, and drug susceptibility testing was performed
using the standard methods. Of the 235 samples screened in group A, 42
Salmonella isolates and 107 Plasmodium spp. were identified. Of the 42
Salmonella isolates, 19 (45.2%) were Salmonella Typhi, 9 (21.4%) S.
Enteritidis, and 7 (16.7%) each of S. Paratyphi and S. Arizonae.
Plasmodium spp.-associated co-infection with Salmonellae was observed
in 16 patients mostly in complicated typhoidal cases and S.
Enteritidis-associated bacteraemia. Fiftty-three of the 206 stool
samples from group B patients were confirmed positive for bacterial
pathogens, made up of 35 Salmonella and 18 Shigella isolates. Of the
Salmonella isolates, 18 (51.4%) were S. Enteritidis, 11 (31.4%) S.
Arizonae, 4 (11.4%) S. Paratyphi, and 2 (5.7%) S. Typhi. There was no
statistically significant difference (p<0.01) in antimicrobial
resistance patterns exhibited among typhoidal Salmonellae isolated in
2000 and 2005. A similar trend in resistance was recorded for
non-typhoidal Salmonellae (p<0.05). For the first time in Lagos,
Nigeria, Salmonella isolates (10-18%) with reduced susceptibility to
both ciprofloxacin and ofloxacin at MIC50 and MIC90 values of 0.015 and
0.03 \ub5g/mL respectively were found. Despite this development,
ciprofloxacin and ofloxacin remain the drug of choice for severe cases
of salmonellosis, although caution should be exercised by clinicians in
their prescriptions such that fluoroquinolone antibiotic therapy is
used only in laboratory-proven cases of typhoid fever and
Salmonella-associated bacteraemia to preserve its efficacy
Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries
BACKGROUND: Artemisinin-based combination therapy (ACT) is the first-line malaria treatment throughout most of the malaria-endemic world. Data on ACT availability, price and market share are needed to provide a firm evidence base from which to assess the current situation concerning quality-assured ACT supply. This paper presents supply side data from ACTwatch outlet surveys in Benin, the Democratic Republic of Congo (DRC), Madagascar, Nigeria, Uganda and Zambia. METHODS: Between March 2009 and June 2010, nationally representative surveys of outlets providing anti-malarials to consumers were conducted. A census of all outlets with the potential to provide anti-malarials was conducted in clusters sampled randomly. RESULTS: 28,263 outlets were censused, 51,158 anti-malarials were audited, and 9,118 providers interviewed. The proportion of public health facilities with at least one first-line quality-assured ACT in stock ranged between 43% and 85%. Among private sector outlets stocking at least one anti-malarial, non-artemisinin therapies, such as chloroquine and sulphadoxine-pyrimethamine, were widely available (> 95% of outlets) as compared to first-line quality-assured ACT (< 25%). In the public/not-for-profit sector, first-line quality-assured ACT was available for free in all countries except Benin and the DRC (US1.29-0.52[IQR: 1.29] per adult equivalent dose respectively). In the private sector, first-line quality-assured ACT was 5-24 times more expensive than non-artemisinin therapies. The exception was Madagascar where, due to national social marketing of subsidized ACT, the price of first-line quality-assured ACT (0.10, 0.36 [IQR: 0.36]). Quality-assured ACT accounted for less than 25% of total anti-malarial volumes; private-sector quality-assured ACT volumes represented less than 6% of the total market share. Most anti-malarials were distributed through the private sector, but often comprised non-artemisinin therapies, and in the DRC and Nigeria, oral artemisinin monotherapies. Provider knowledge of the first-line treatment was significantly lower in the private sector than in the public/not-for-profit sector. CONCLUSIONS: These standardized, nationally representative results demonstrate the typically low availability, low market share and high prices of ACT, in the private sector where most anti-malarials are accessed, with some exceptions. The results confirm that there is substantial room to improve availability and affordability of ACT treatment in the surveyed countries. The data will also be useful for monitoring the impact of interventions such as the Affordable Medicines Facility for malaria
Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries
BACKGROUND: Access to artemisinin-based combination therapy (ACT) remains limited in high malaria-burden countries, and there are concerns that the poorest people are particularly disadvantaged. This paper presents new evidence on household treatment-seeking behaviour in six African countries. These data provide a baseline for monitoring interventions to increase ACT coverage, such as the Affordable Medicines Facility for malaria (AMFm). METHODS: Nationally representative household surveys were conducted in Benin, the Democratic Republic of Congo (DRC), Madagascar, Nigeria, Uganda and Zambia between 2008 and 2010. Caregivers responded to questions about management of recent fevers in children under five. Treatment indicators were tabulated across countries, and differences in case management provided by the public versus private sector were examined using chi-square tests. Logistic regression was used to test for association between socioeconomic status and 1) malaria blood testing, and 2) ACT treatment. RESULTS: Fever treatment with an ACT is low in Benin (10%), the DRC (5%), Madagascar (3%) and Nigeria (5%), but higher in Uganda (21%) and Zambia (21%). The wealthiest children are significantly more likely to receive ACT compared to the poorest children in Benin (OR = 2.68, 95% CI = 1.12-6.42); the DRC (OR = 2.18, 95% CI = 1.12-4.24); Madagascar (OR = 5.37, 95% CI = 1.58-18.24); and Nigeria (OR = 6.59, 95% CI = 2.73-15.89). Most caregivers seek treatment outside of the home, and private sector outlets are commonly the sole external source of treatment (except in Zambia). However, children treated in the public sector are significantly more likely to receive ACT treatment than those treated in the private sector (except in Madagascar). Nonetheless, levels of testing and ACT treatment in the public sector are low. Few caregivers name the national first-line drug as most effective for treating malaria in Madagascar (2%), the DRC (2%), Nigeria (4%) and Benin (10%). Awareness is higher in Zambia (49%) and Uganda (33%). CONCLUSIONS: Levels of effective fever treatment are low and inequitable in many contexts. The private sector is frequently accessed however case management practices are relatively poor in comparison with the public sector. Supporting interventions to inform caregiver demand for ACT and to improve provider behaviour in both the public and private sectors are needed to achieve maximum gains in the context of improved access to effective treatment
Staphylococcal bacteraemia among human immunodeficiency virus positive patients at a screening center in Lagos, Nigeria
Bacteraemia due to Staphylococcus aureus in Human immunodeficiency virus (HIV) – positive patients is associated with increased mortality rate. The present study aimed at determining the species distribution and occurrence of staphylococcal bacteraemia in HIV – positive patients in Lagos, Nigeria. Staphylococcal blood stream infection in febrile HIV patients was investigated by culture technique. The antibiotic resistance pattern was investigated using the disk diffusion and methicillin resistance was confirmed by the salt agar methods. The genetic relatedness of S. aureus was determined using Pulsed Field Gel Electrophoresis (PFGE). Eighty-six patients comprising 47 (55%) female and 39 (45%) male, median aged 34 years took part in the study. Staphylococci were identified in 16 (18.6%) patients; 13 (15.1%) and 3 (3.5%) with single and dual Staphylococcus species respectively. The isolates consisted of S. aureus (7 patients), followed by S. haemolyticus (4 patients). Of the thirteen (13) antibiotics tested, isolates were resistant to ampicillin (AMP; 89.5%), tetracycline (TET; 68.4%), cloxacillin (CXC; 89.5%), oxacillin (OXA; 68.4%); chloramphenicol (CHL; 57.9%) and trimethoprim-sulphamethoxazole (SXT; 63.1%). The overall percentage of all the isolates resistant to gentamicin, erythromycin and amoxicillin-clavulanic acid was less than 50%. All the isolates were susceptible to ciprofloxacin and vancomycin and none was positive for methicillin resistance except a strain of S. haemolyticus. Significant genetic diversity was observed among the S. aureus isolates with a predominant pulsotype A. The two isolates with pulsotype A had identical resistotype (AMP, ERY, TET, CXC, SXT). Other PFGE patterns were represented by single isolates except pulsotype C which had a subtype. In these patients, the most frequent Staphylococcus species isolated was S. aureus and the results revealed that clonal dissemination of a virulent pulsotype of S. aureus among this population is plausible and should be a cause for concern